Skip to main content

Table 3 Factors associated with VA failure after VAIVT in univariate Cox regression model

From: Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

 

HR

95% CI

p value

Older age

0.78

0.35–1.65

0.52

Sex (male)

1.95

0.75–6.64

0.18

Etiology of ESRD

 DN

1.30

0.61–2.74

0.50

 NS

0.58

0.17–1.50

0.28

 CGN

0.96

0.32–2.34

0.94

 ADPKD

 IgAN

0.81

0.20–4.15

0.78

 Other or unknown

1.13

0.27–3.23

0.85

Smoking history

0.83

0.38–1.92

0.64

DM

1.95

0.87–4.95

0.11

Dyslipidemia

1.46

0.69–3.31

0.33

CVD

0.75

0.35–1.58

0.45

 IHD

0.74

0.22–1.93

0.57

 CHF

1.25

0.20–4.20

0.77

 Stroke

0.27

0.02–1.29

0.12

PAD

0.56

0.13–1.60

0.31

RASI

1.69

0.80–3.71

0.17

Statin

1.41

0.67–3.10

0.37

Warfarin

0.61

0.10–2.03

0.46

Antiplatelet agents

0.45

0.21–0.95

0.036

AVF anastomosis type (%)

 Radiocephalic

3.22

0.96–20.0

0.060

 Brachiocephalic

0.36

0.06–1.21

0.11

  1. We defined individuals aged > 71 years as “the older age”
  2. VA vascular access, VAIVT vascular access intervention therapy, HR hazard ratio, CI confidence interval, ESRD end-stage renal disease, DN diabetic nephropathy, NS nephrosclerosis, CGN chronic glomerulonephritis, ADPKD autosomal dominant polycystic kidney disease, IgAN IgA nephropathy, DM diabetes mellitus, CVD cardiovascular disease, IHD ischemic heart disease, CHF congestive heart failure, PAD peripheral artery disease, RASI renin–angiotensin–aldosterone system inhibitor, AVF arteriovenous fistula